Boosting extracellular vesicle secretion

Lior Debbi; Shaowei Guo; Dina Safina; Shulamit Levenberg

doi:10.1016/j.biotechadv.2022.107983

Boosting extracellular vesicle secretion

Biotechnol Adv. 2022 Oct:59:107983. doi: 10.1016/j.biotechadv.2022.107983. Epub 2022 May 16.

Authors

Lior Debbi¹, Shaowei Guo², Dina Safina¹, Shulamit Levenberg³

Affiliations

¹ Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
² The First Affiliated Hospital, Shantou University Medical College, Shantou, China.
³ Faculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: shulamit@bm.technion.ac.il.

Abstract

In recent years, extracellular vesicles (EVs), specifically exosomes, have emerged as a promising strategy for treating a wide spectrum of pathologies, such as cancer and COVID-19, as well as promoting tissue regeneration in various conditions, including cardiomyopathies and spinal cord injuries. Despite the great potential of EV-based therapies, poor yield and unscalable production of EVs remain big challenges to overcome to translate these types of treatment to clinical practices. Here, we review different strategies for enhancing EV yield by physical, biological or chemical means. Some of these novel approaches can lead to about 100-fold increase in EV production yield, thus bringing closer the clinical translation with regard to scalability and efficiency.

Keywords: Drug delivery; Exosomes; Extracellular vesicles; Large-scale.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Exosomes*
Extracellular Vesicles*
Humans
Neoplasms*